Fundraising FoxAventera Antibodies
Lund, SE · 1 known investors
Find your way into Aventera Antibodies
Sign up to see every warm intro you have to Aventera Antibodies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aventera Antibodies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aventera Antibodies is a preclinical biotech developing a first-in-class precision immunotherapy — an engineered monoclonal antibody — against invasive Group A Streptococcal (iGAS) infections, with first-in-human trials planned for 2028. The therapy is intended to be paired with rapid Strep-A diagnostics to enable early clinical intervention.
Founders & leadership
AI
Arman IzadiCEO & FounderArman Izadi is a physician-scientist with clinical training from Karolinska University Hospital and research experience in Fc-engineered antibodies at Lund University. He is CEO and founder of Aventera Antibodies, a biotech company developing engineered monoclonal antibodies to treat invasive Group A Streptococcal infections.
PN
Pontus NordenfeltChairman of the Scientific Advisory Board, Board of Directors, FounderPontus Nordenfelt holds a PhD in Cell Biology from Lund University and an MSc in Chemical Engineering/Biotechnology from Lund Institute of Technology; he was an Associate Professor in Infection Medicine at Lund University with postdoctoral training at Harvard Medical School under Timothy Springer and at Sick Kids Toronto, and previously led a research group studying host-pathogen interactions and antibody biology.
Investors · 1
Frequently asked questions
- What does Aventera Antibodies do?
- Aventera Antibodies is a preclinical biotech developing a first-in-class precision immunotherapy — an engineered monoclonal antibody — against invasive Group A Streptococcal (iGAS) infections, with first-in-human trials planned for 2028. The therapy is intended to be paired with rapid Strep-A diagnostics to enable early clinical intervention.
- Who founded Aventera Antibodies?
- Aventera Antibodies was founded by Arman Izadi, Pontus Nordenfelt.
- Who are Aventera Antibodies's investors?
- Aventera Antibodies's investors include LU Innovation.
- Where is Aventera Antibodies headquartered?
- Aventera Antibodies is headquartered in Lund, SE.